How to Get Leqvio (Inclisiran) in Delaware

What Is Leqvio and Why Does LDL Reduction Matter

Leqvio (inclisiran) is the first small interfering RNA (siRNA) therapy approved by the FDA for LDL-C reduction. It works by silencing the hepatic PCSK9 mRNA, cutting PCSK9 protein production at the source rather than blocking circulating PCSK9 protein. The result is a sustained, twice-yearly reduction in LDL cholesterol that does not depend on daily pill adherence. FDA approval was granted December 22, 2021.

Elevated LDL-C drives plaque accumulation in coronary and carotid arteries. The American College of Cardiology 2022 guidelines state that patients with clinical ASCVD or HeFH who cannot reach target LDL-C on statin and ezetimibe therapy are candidates for PCSK9-pathway inhibition, including inclisiran. The guideline text is available through the AHA Journals.

For Delaware residents, the practical question is not whether Leqvio works, but how to get through the prescriber, payer, and pharmacy steps quickly. Each of those steps has a specific process in Delaware, and each is covered in detail below.

The Evidence Behind Inclisiran: ORION-10 and ORION-11

The key data that led to FDA approval came from two parallel phase-3 trials. ORION-10 and ORION-11 (N=3,457 combined, published in NEJM 2020) enrolled adults with ASCVD (ORION-10) or ASCVD risk equivalents including HeFH (ORION-11), all on maximally tolerated statin therapy. At month 17, inclisiran 284 mg given subcutaneously at Day 1, Day 90, and every 6 months thereafter produced a time-averaged LDL-C reduction of 50% versus placebo (P<0.001). The placebo arms showed no meaningful LDL-C change.

Injection-site reactions were the most common adverse event, occurring in 2.6% of inclisiran participants versus 0.9% of placebo participants. Liver enzyme elevations did not differ significantly between groups. No myopathy signal emerged, which separates inclisiran from the tolerability concerns some patients associate with high-intensity statins.

The ORION-11 data are particularly relevant for Delaware's HeFH population. Baseline LDL-C in that trial averaged 151 mg/dL. After the loading doses and first maintenance injection, mean LDL-C fell to approximately 67 mg/dL. That magnitude of reduction is clinically meaningful for a patient population where cardiovascular events occur 20 years earlier than in the general population. HeFH epidemiology and risk data are catalogued by the NIH Genetics Home Reference.

Who Qualifies for Leqvio in Delaware

Two FDA-approved indications apply in Delaware:

Heterozygous Familial Hypercholesterolemia (HeFH). Diagnosis requires a clinical diagnosis using the Dutch Lipid Clinic Network (DLCN) score of 6 or higher, a confirmatory genetic test showing a pathogenic LDL receptor, ApoB, or PCSK9 mutation, or a documented family history consistent with HeFH plus an LDL-C >190 mg/dL. Most Delaware Medicaid managed care organizations require one of these three pathways documented in the chart before approving a PA request.

Clinical ASCVD. This covers a prior myocardial infarction, ischemic stroke, symptomatic peripheral arterial disease, or coronary revascularization. Patients must also be on maximally tolerated statin therapy and have LDL-C ≥70 mg/dL at the time of the PA request. Delaware's Highmark, Aetna, and BCBS plans each use that 70 mg/dL threshold, though United Healthcare Delaware plans have at times required LDL-C ≥100 mg/dL for non-FH ASCVD patients. Always pull the current formulary PA criteria before submitting.

Patients who do not meet either indication may still access inclisiran through a licensed 503A compounding pharmacy in Delaware, though compounded inclisiran is not FDA-approved and carries different regulatory status. That option is discussed in the pharmacy section below.

Finding a Prescriber in Delaware: In-Person and Telehealth Options

Delaware permits telehealth prescribing for inclisiran under Delaware Code Title 24, provided the prescriber holds an active Delaware license and conducts a clinically appropriate evaluation. A telehealth visit satisfies the in-person evaluation requirement for inclisiran because the drug itself is administered by a health care professional, not self-injected at home. The prescriber's job at the telehealth visit is to review the lipid panel, confirm the indication, rule out contraindications, and submit the PA.

Cardiologists and lipid specialists in Delaware's major health systems (ChristianaCare, Bayhealth, and Beebe Healthcare) are familiar with inclisiran PA workflows. Wait times for a new cardiology appointment in Delaware average 3 to 6 weeks. A telehealth lipid consultation through a platform licensed in Delaware can compress that timeline to 3 to 7 days.

The HealthRX clinical team uses a four-step evaluation framework for inclisiran candidates in Delaware:

1. Lipid panel review. Confirm fasting LDL-C on current statin dose. If the patient is not on a statin, document intolerance with at least one prior statin trial in the chart.
2. Indication confirmation. Assign DLCN score for possible HeFH or document ASCVD history with ICD-10 codes (I25.10 for CAD, I63.x for ischemic stroke, I73.9 for PAD).
3. Contraindication screen. No absolute contraindications exist in the FDA label, but pregnancy (Category not formally assigned; avoid) and active hepatic disease require clinical judgment.
4. PA submission. Submit with the lipid panel dated within 12 months, the statin trial documentation, and the DLCN score or ASCVD diagnosis code.

This framework is not a substitute for individualized clinical judgment, and every patient should be evaluated by their own licensed provider.

NP and PA prescribing in Delaware. Nurse practitioners in Delaware operate under a collaborative practice agreement with a supervising physician. Both NPs and PAs may prescribe inclisiran within their scope if the collaborative agreement covers lipid management. Delaware passed SB 72 in 2021, expanding NP prescriptive authority, so most NPs practicing in cardiology or primary care in Delaware can now submit Leqvio prescriptions and PA requests without a per-prescription physician co-signature.

Lab Requirements Before Starting Leqvio in Delaware

A baseline lipid panel is the minimum required lab. The ACC/AHA cholesterol guideline recommends a fasting lipid panel, though non-fasting total cholesterol and LDL-C calculated by the Friedewald or Martin-Hopkins equation is acceptable for PA purposes in most Delaware plans.

Beyond the lipid panel, most Delaware payers also require:

• AST and ALT within 6 months, because inclisiran is hepatically cleared via the asialoglycoprotein receptor. No dose adjustment is needed for mild-to-moderate hepatic impairment, but severe hepatic impairment (Child-Pugh C) has not been studied and most prescribers order baseline LFTs to document baseline status.
• Serum creatinine or eGFR. No dose adjustment is required for renal impairment, but the ORION trials excluded patients with eGFR <30 mL/min/1.73 m², so documentation of renal function is standard practice.
• HbA1c or fasting glucose if the patient has diabetes, because statin-associated diabetes risk is a common reason patients escalate to non-statin therapy, and documenting glycemic status protects against future PA challenges.

Delaware Medicaid typically requires the lipid panel to be dated within 12 months of the PA request. Commercial payers vary; Highmark Delaware has accepted panels up to 18 months old when the clinical notes confirm the patient has been continuously on the same statin dose during that period.

Navigating Prior Authorization in Delaware

Prior authorization is the most common point of delay. Delaware law (Title 18, Section 3371) requires insurers to issue a PA decision within 72 hours for urgent requests and within 15 calendar days for standard requests. In practice, inclisiran PAs for commercial plans are frequently returned within 5 to 7 business days when submitted with complete documentation on the first attempt.

The documentation package for a first-time PA submission in Delaware should include:

• The fasting lipid panel showing LDL-C on current statin (date, lab name, fasting status)
• The statin name, dose, and duration on that dose (or intolerance documentation with the specific adverse effect)
• Ezetimibe trial documentation if the payer requires dual non-statin therapy failure (Highmark and BCBS Delaware do; Aetna Delaware does not for FH patients)
• The ICD-10 diagnosis code (E78.01 for HeFH, I25.10 for ASCVD)
• The prescriber's NPI and Delaware license number
• A letter of medical necessity if the chart notes alone do not make the clinical rationale explicit

If the PA is denied, Delaware's external appeal process under the Insurance Commissioner's office allows a 45-day window to request independent review. Denial rates for inclisiran drop significantly on appeal when the denial is "step therapy required" and the chart documents ezetimibe intolerance or failure.

Delaware Medicaid's Diamond State Health Plan covers inclisiran with PA for both FH and ASCVD indications. The PA criteria mirror the FDA label closely: maximally tolerated statin, LDL-C above threshold, confirmed indication. Redetermination is required every 12 months.

Pharmacy Logistics: Specialty Pharmacies and 503A Compounders in Delaware

Leqvio is not a drug patients pick up at a retail pharmacy. It is classified as a specialty medication distributed through a limited specialty pharmacy network that includes CVS Specialty, Accredo (Express Scripts), and Diplomat Pharmacy. Each of these ships to Delaware addresses and coordinates the cold-chain requirement (Leqvio must be stored at 2 to 8 degrees Celsius).

The typical workflow after PA approval:

1. The prescriber sends the prescription to the specialty pharmacy or the Novartis patient support hub (Leqvio Together).
2. The pharmacy verifies insurance, ships to the prescribing office or to a home-nursing agency coordinating the injection.
3. The injection is administered by the prescriber or a delegated licensed clinical professional (RN, PA, NP, or physician).

503A compounding in Delaware. Delaware's State Board of Pharmacy licenses 503A compounders to prepare patient-specific compounded preparations. A 503A pharmacy in Delaware may compound an inclisiran-like preparation under a valid patient-specific prescription, but compounded inclisiran is not the same as FDA-approved Leqvio, has not completed the ORION efficacy and safety trials, and may have different bioavailability. Patients who cannot afford Leqvio or do not qualify for the commercial indication may explore this option, but only with full informed consent from their prescriber. The FDA's guidance on compounding and the FDCA 503A exemption is available at FDA.gov.

Time to first injection. From the date a complete prescription and PA package is submitted, Delaware patients typically receive their first injection within 10 to 21 days. PA review accounts for 5 to 7 days, specialty pharmacy dispensing and shipping adds 2 to 5 days, and scheduling the injection visit adds another 3 to 9 days depending on the patient's chosen clinical site. Telehealth-initiated prescriptions do not add time; the prescriber submits the PA and prescription electronically on the day of the visit.

Cost and Financial Assistance in Delaware

Leqvio's list price is approximately $3,600 per injection, or $7,200 per year after the loading doses. Most commercially insured Delaware patients pay $0 to $50 per dose after specialty pharmacy benefit application, particularly those on Highmark or BCBS plans where Leqvio is on the specialty tier with a co-pay cap.

Novartis operates the Leqvio Together copay assistance program. Eligible commercially insured patients pay no more than $10 per injection for up to 12 injections. Patients who are uninsured or underinsured may qualify for the Novartis Patient Assistance Program (PAP), which provides Leqvio at no cost based on income thresholds. Delaware's DHSS also administers the Delaware Prescription Assistance Program (DPAP) for residents who fall below 200% of the federal poverty line.

Delaware Medicaid patients covered under Diamond State Health Plan who receive PA approval pay $0 copay for Leqvio under the state's preferred drug list provisions.

Transferring an Existing Leqvio Prescription to Delaware

Patients relocating to Delaware who have an active Leqvio prescription from another state face a straightforward but time-specific process. Specialty pharmacy prescriptions for inclisiran are written on a per-course basis, and most prescriptions specify the administering site. A Delaware-licensed prescriber must issue a new prescription because inclisiran requires in-state prescribing authority for continuing PA approval.

The transfer process involves:

• Obtaining medical records from the prior prescriber documenting the indication, baseline lipid panel, statin history, and prior PA approval letters
• Scheduling a new-patient visit with a Delaware-licensed prescriber (telehealth is acceptable)
• Submitting a new PA to the patient's Delaware insurance plan, because PA approvals do not transfer across state lines or across payer networks

Patients should time this transition carefully. Inclisiran's 6-month dosing interval means a delay of even 8 to 10 weeks between injections is unlikely to result in a clinically significant LDL-C rebound based on ORION-11 pharmacokinetic modeling, but re-establishing care before the scheduled injection date is best practice. ORION-11 pharmacokinetic data is published in the NEJM.

The American Heart Association's 2023 scientific statement on PCSK9 inhibition notes: "Maintaining continuity of LDL-lowering therapy during transitions of care is associated with lower rates of recurrent cardiovascular events in high-risk patients." That statement is indexed at the AHA Journals.

What to Expect After the First Injection

After the Day 1 injection, the next dose is given at Day 90 (3 months). After that, injections occur every 6 months indefinitely, because stopping inclisiran allows LDL-C to return to baseline within approximately 6 months as PCSK9 production resumes. Patients should have a repeat fasting lipid panel drawn 3 months after each injection to confirm response.

In ORION-10 to 73% of inclisiran participants achieved LDL-C <70 mg/dL by month 17 compared with 7% of placebo participants (P<0.001). Full ORION-10 data are available at PubMed. Non-responders (defined as <30% LDL-C reduction at month 3) are uncommon but should prompt reassessment of injection technique and patient adherence to statin therapy, not dose escalation, because no higher-dose inclisiran formulation has completed phase-3 trials.

Injection-site reactions are mild and transient in most patients. The standard injection site is the abdomen, upper arm, or thigh. Delaware patients receiving injections at home through a nursing agency should confirm the agency's clinicians are trained in subcutaneous biologics administration, not just insulin delivery, because the volume and needle gauge differ.

Delaware physicians following patients on inclisiran should document LDL-C response in the chart at each injection visit. That documentation supports PA renewal and provides the longitudinal lipid record that informs future cardiovascular risk assessment.

A Note on Inclisiran Versus Evolocumab and Alirocumab

Delaware prescribers sometimes ask whether inclisiran or the biologic PCSK9 inhibitors, evolocumab (Repatha) and alirocumab (Praluent), are preferable. The LDL-C reduction is broadly comparable. Evolocumab and alirocumab demonstrated cardiovascular outcomes benefits in FOURIER (N=27,564) and ODYSSEY OUTCOMES (N=18,924) respectively, whereas inclisiran's cardiovascular outcomes trial (ORION-4) reported its primary results in 2024. Prescribers who require proven outcomes data before prescribing may prefer the biologics for now.

The practical advantage of inclisiran is the twice-yearly dosing versus every-2-week or monthly self-injection for the biologics. For Delaware patients with needle aversion, adherence challenges, or complex polypharmacy regimens, that dosing simplicity may translate to better real-world LDL-C control even if the per-injection cost to the payer is higher.

The ACC Expert Consensus Decision Pathway on non-statin therapy states: "For patients where adherence to frequent self-injection is a concern, inclisiran administered by a health professional twice yearly offers a clinically relevant adherence advantage." That pathway document is available via the AHA Journals.